Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 4

3(42.9%)

Phase 1

1(14.3%)

7Total

N/A(3)

Phase 4(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02808000Phase 4Completed

BIP Foley in Prevention of CAUTI at Rehab Station

Role: lead

NCT03976557Not ApplicableTerminated

BIP CVC in Access Center at Danderyd Hospital, Stockholm, Sweden

Role: lead

NCT04242706Phase 4Completed

VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs

Role: lead

NCT02284438Not ApplicableCompleted

Biofilm Formation on Different Endotracheal Tube Materials

Role: collaborator

NCT03868241Phase 1Completed

Coated Devices to Decrease Infection in the Intensive Care Unit

Role: collaborator

NCT02811380Phase 4Completed

BIP CVC Clinical Safety and Performance Study

Role: lead

NCT01682486Not ApplicableCompleted

BIP ETT Clinical Tolerability, Safety and Performance Study

Role: lead

All 7 trials loaded